Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the Virtual BTIG Annual Biotech Conference on Tuesday, August 10, 2021 at 2:50 p.m. ET.
In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
ABOUT AURINIA
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005377/en/
Aurinia Pharmaceuticals Inc. Aktie
Die Community ist bei Aurinia Pharmaceuticals Inc. noch unentschieden: Nur wenige Einschätzungen.
Das höhere Kursziel von 10 € im Vergleich zum aktuellen Kurs von 5.04 € für Aurinia Pharmaceuticals Inc. führt zu einem positiven Potenzial von 98.57%.
